Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial:

- Regimen G
- Regimen F
- Regimen C
- Regimen E
- Regimen D
- Regimen B
- Regimen A

Common Protocol and Shared Infrastructure

- Screen for eligibility
- Randomization 3:1
- Active
- Placebo
- ENROLLMENT COMPLETE
- ENROLLING
- ENROLLING

SEELOS THERAPEUTICS
Calico
DENALI THERAPEUTICS
Therapy Evaluation Committee

- All investigational products in the Platform Trial were chosen by a committee of expert ALS scientists and clinicians.

- Industry partners from selected companies work with the Healey Center Trial Design Team, the Northeast ALS Consortium (NEALS), Barrow Neurological Institute and Berry Consultants to tailor a new regimen to their experimental drug.

- Each investigational product added to the Platform Trial is believed to have an equal chance of success for all forms of ALS based on available scientific evidence.

Criteria for selection included:

- Robust preclinical data (data from the lab that support the scientific rationale for testing these products in ALS).

- Previous human experience in ALS or other neurological diseases (to support the dose, safety and target engagement of the product and its inclusion in a late-stage trial such as the Platform Trial).
Common Protocol – Endpoints

Primary Endpoint
- Change in disease severity through 24 weeks
- ALS Functional Rating Scale-Revised (ALSFRS-R) + Mortality
- Potential to provide confirmatory evidence with overall type I error of 5%

Secondary Endpoints
1. Change in respiratory function - slow vital capacity (SVC)
2. Change in muscle strength - hand held dynamometry (HHD)
3. Survival

Safety Endpoints

Biomarkers and Exploratory Endpoints (DNA, NfL, Speech app, Home Spirometry)
Enrollment Update: Regimen F and Regimen G

Participants consented to Master Protocol since RGF and RGG initiated

Participants assigned to RGF or RGG

Participants randomized within RGF or RGG

Thank You
for your partnership in ALS research

(as of 10/26/23)
# Checking Site Status Online

## List of Participating Sites

Sites marked "Recruiting" are currently enrolling participants. Sites marked "Active, Not recruiting" are active in the Platform Trial (for example, they are following participants in ongoing regimens that have already completed enrollment) but are not enrolling new participants at this time.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Trial Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barrow Neurological Institute</td>
<td>AZ</td>
<td>Recruiting</td>
<td>Whitney Dailey</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Sophia Mostowy</td>
</tr>
<tr>
<td>Forbes Norris MDA/ALS Research Center, California</td>
<td>CA</td>
<td>Recruiting</td>
<td>Teji Dulai</td>
</tr>
<tr>
<td>Pacific Medical Center</td>
<td>CA</td>
<td>Recruiting</td>
<td>Mary H. Berganza</td>
</tr>
</tbody>
</table>

[https://bit.ly/3g2NZr5](https://bit.ly/3g2NZr5)
This public webpage provides:

1. General Brochure and Biomarkers Brochure
2. Overview of science behind Regimen F and Regimen G
3. Links to download relevant brochures, including the Lumbar Puncture Brochure
4. Links to view relevant videos and webinar recordings

Regimen F: ABBV-CLS-7262, by Calico and AbbVie- Now Recruiting
- Watch a webinar about the science behind ABBV-CLS-7262
- Watch this video for more information on the mechanism of action behind ABBV-CLS-7262.
- Download Regimen F Brochure
- Download Lumbar Puncture Brochure
- Step by Step Guide to Lumbar Punctures: Watch short video

Regimen G: DNL343, by Denali Therapeutics
- Download Regimen G Brochure
- Watch a webinar about the science behind DNL343

https://www.massgeneral.org/neurology/als/research/first-platform-trial-treatments
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: https://bit.ly/3r6Nd2L
ALS Link sign-up: https://bit.ly/3o2Ds3m

Upcoming Webinars:
November 2nd- weekly Q&A
November 9th- weekly Q&A and EAP discussion with Dr. Suma Babu (Mass General)
November 16th- Regimen G science Q&A with Denali Therapeutics